Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Gaspar MC, Couet W, Olivier JC, Pais AA, Sousa JJ.

Eur J Clin Microbiol Infect Dis. 2013 Oct;32(10):1231-52. doi: 10.1007/s10096-013-1876-y. Epub 2013 Apr 26. Review.

PMID:
23619573
2.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
3.

Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Greally P, Whitaker P, Peckham D.

Curr Med Res Opin. 2012 Jun;28(6):1059-67. doi: 10.1185/03007995.2012.674500. Epub 2012 May 10. Review.

PMID:
22401602
4.

Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Assael BM.

Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73. doi: 10.1586/eri.11.131. Review.

PMID:
22029514
5.

Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.

Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, Reimert CM, Høiby N, Koch C.

Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1190-6.

PMID:
9351621
6.

Clonal epidemiology of Pseudomonas aeruginosa in cystic fibrosis.

Cramer N, Wiehlmann L, Tümmler B.

Int J Med Microbiol. 2010 Dec;300(8):526-33. doi: 10.1016/j.ijmm.2010.08.004. Epub 2010 Oct 14. Review.

PMID:
20951087
7.

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates.

Tramper-Stranders GA, van der Ent CK, Molin S, Yang L, Hansen SK, Rau MH, Ciofu O, Johansen HK, Wolfs TF.

Clin Microbiol Infect. 2012 Jun;18(6):567-74. doi: 10.1111/j.1469-0691.2011.03627.x. Epub 2011 Aug 29.

8.
9.

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.

Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J.

Expert Opin Pharmacother. 2013 Jun;14(9):1135-49. doi: 10.1517/14656566.2013.790366. Epub 2013 Apr 16. Review.

PMID:
23586963
10.

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.

Ballmann M, Smyth A, Geller DE.

Respir Med. 2011 Dec;105 Suppl 2:S2-8. doi: 10.1016/S0954-6111(11)70021-X.

11.
12.

Pseudomonas aeruginosa and the airways disease of cystic fibrosis.

Hata JS, Fick RB Jr.

Clin Chest Med. 1988 Dec;9(4):679-89. Review.

PMID:
3148384
13.

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.

Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2009 Sep;53(9):3923-8. doi: 10.1128/AAC.00268-09. Epub 2009 Jun 15.

14.

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

Ratjen F, Brockhaus F, Angyalosi G.

J Cyst Fibros. 2009 Dec;8(6):361-9. doi: 10.1016/j.jcf.2009.08.004. Epub 2009 Sep 10. Review.

15.

Nebulised anti-pseudomonal antibiotics for cystic fibrosis.

Ryan G, Mukhopadhyay S, Singh M.

Cochrane Database Syst Rev. 2003;(3):CD001021. Review. Update in: Cochrane Database Syst Rev. 2011;(3):CD001021.

PMID:
12917897
16.

Pseudomonal infection in cystic fibrosis: the battle continues.

Elkin S, Geddes D.

Expert Rev Anti Infect Ther. 2003 Dec;1(4):609-18. Review.

PMID:
15482158
17.

Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Ehsan Z, Clancy JP.

Future Microbiol. 2015;10(12):1901-12. doi: 10.2217/fmb.15.117. Epub 2015 Nov 17. Review.

18.

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.

Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A; Scandinavian CF Study Consortium (SCFSC).

J Cyst Fibros. 2009 Mar;8(2):135-42. doi: 10.1016/j.jcf.2008.11.001. Epub 2009 Jan 20.

19.

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.

Paediatr Drugs. 2007;9 Suppl 1:21-31.

PMID:
17536872
20.

Nebulised anti-pseudomonal antibiotics for cystic fibrosis.

Ryan G, Mukhopadhyay S, Singh M.

Cochrane Database Syst Rev. 2000;(2):CD001021. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD001021.

PMID:
10796732

Supplemental Content

Support Center